Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CDKN2A |
Variant | A17fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | CDKN2A A17fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 17 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). A17fs has not been characterized, however, due to the effects of other truncation mutations downstream of A17 (PMID: 9053859, PMID: 8668202), is predicted to lead to a loss of Cdkn2a protein function. |
Associated Drug Resistance | |
Category Variants Paths |
CDKN2A mutant CDKN2A inact mut CDKN2A A17fs |
Transcript | NM_000077.5 |
gDNA | chr9:g.(21974779_21974780) |
cDNA | c.(49_48) |
Protein | p.A17fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001363763.2 | chr9:g.(21971157_21971158) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
XM_047422596.1 | chr9:g.(21971157_21971158) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
XM_047422598.1 | chr9:g.(21971157_21971158) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
XM_047422597.1 | chr9:g.(21971157_21971158) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
XM_011517675.3 | chr9:g.(21974779_21974780) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
NM_001195132.2 | chr9:g.(21974779_21974780) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
NM_058197.5 | chr9:g.(21974779_21974780) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
XM_011517676.3 | chr9:g.(21974779_21974780) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
NM_000077.5 | chr9:g.(21974779_21974780) | c.(49_48) | p.A17fs | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A A17fs | lung adenocarcinoma | predicted - sensitive | Palbociclib | Case Reports/Case Series | Actionable | In a Phase II trial (TAPUR), Ibrance (palbociclib) treatment resulted in a partial response in a patient with lung adenocarcinoma harboring CDKN2A A17fs (PMID: 35050752; NCT02693535). | 35050752 |